Literature DB >> 11122799

Vascular endothelial growth factor in ovarian cancer.

D A Hazelton1, T C Hamilton.   

Abstract

Tumor growth requires nutrients and oxygen. Both nutrients and oxygen are provided via the vasculature. Thus, when a tumor increases in volume, new blood vessels must form and invade the expanding tumor. This process, called angiogenesis, has theoretical significance in the context of ovarian cancer for two reasons. First, the process of angiogenesis and vessel regression occurs in a tightly controlled way as part of normal ovarian function. This suggests that at least some ovarian cells are primed to produce the paracrine stimulus needed for new blood vessel growth and that, on transformation, this capability is present early in tumor development. Second, the characteristically large size of ovarian tumors indicates that angiogenesis is mandatory to sustain the tumor. In this article, we review the experimental and clinical correlative data that support the hypothesis that ovarian cancers are highly angiogenic. Because a critical component of angiogenesis is the paracrine and autocrine production of vascular endothelial cell growth factor, there is substantial focus on this topic.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11122799     DOI: 10.1007/s11912-999-0011-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  46 in total

1.  Angiogenesis in primary and metastatic epithelial ovarian carcinoma.

Authors:  O Abulafia; W E Triest; D M Sherer
Journal:  Am J Obstet Gynecol       Date:  1997-09       Impact factor: 8.661

2.  Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis.

Authors:  W M Schoell; D Pieber; O Reich; M Lahousen; M Janicek; F Guecer; R Winter
Journal:  Cancer       Date:  1997-12-15       Impact factor: 6.860

3.  Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis.

Authors:  J McLaren; A Prentice; D S Charnock-Jones; S K Smith
Journal:  Hum Reprod       Date:  1996-01       Impact factor: 6.918

4.  Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.

Authors:  C Wiesmann; G Fuh; H W Christinger; C Eigenbrot; J A Wells; A M de Vos
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

5.  Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice.

Authors:  J Yoneda; H Kuniyasu; M A Crispens; J E Price; C D Bucana; I J Fidler
Journal:  J Natl Cancer Inst       Date:  1998-03-18       Impact factor: 13.506

6.  Biologic implications of the expression of vascular endothelial growth factor subtypes in ovarian carcinoma.

Authors:  J Fujimoto; H Sakaguchi; R Hirose; S Ichigo; T Tamaya
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

7.  Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.

Authors:  A Kraft; K Weindel; A Ochs; C Marth; J Zmija; P Schumacher; C Unger; D Marmé; G Gastl
Journal:  Cancer       Date:  1999-01-01       Impact factor: 6.860

8.  [Expression and subtype analysis of vascular endothelial growth factor (VEGF) and its receptor (flt-1) in human ovarian tumors].

Authors:  Y Ishii
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1995-02

9.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome.

Authors:  J Neulen; Z Yan; S Raczek; K Weindel; C Keck; H A Weich; D Marmé; M Breckwoldt
Journal:  J Clin Endocrinol Metab       Date:  1995-06       Impact factor: 5.958

10.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Authors:  P Salven; A Lymboussaki; P Heikkilä; H Jääskela-Saari; B Enholm; K Aase; G von Euler; U Eriksson; K Alitalo; H Joensuu
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

View more
  10 in total

1.  Evaluation of a hypoxia regulated gene panel in ovarian cancer.

Authors:  Amanda F Baker; Scott W Malm; Ritu Pandey; Cindy Laughren; Haiyan Cui; Denise Roe; Setsuko K Chambers
Journal:  Cancer Microenviron       Date:  2015-05-22

2.  Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.

Authors:  Satoshi Tsunetoh; Yoshito Terai; Hiroshi Sasaki; Akiko Tanabe; Yoshimichi Tanaka; Tatsuharu Sekijima; Satoe Fujioka; Hiroshi Kawaguchi; Masanori Kanemura; Yoshiki Yamashita; Masahide Ohmichi
Journal:  Cancer Biol Ther       Date:  2010-12-01       Impact factor: 4.742

3.  Effects of a selective cyclooxygenase-1 inhibitor in SKOV-3 ovarian carcinoma xenograft-bearing mice.

Authors:  Wei Li; Zhong-lei Ji; Guang-chao Zhuo; Ru-jun Xu; Jie Wang; Hong-ru Jiang
Journal:  Med Oncol       Date:  2009-02-24       Impact factor: 3.064

4.  Prognostic and predictive value of serum vascular endothelial growth factor (VEGF) in squamous cell carcinoma of the head and neck.

Authors:  Bijan Khademi; Mehdi Soleimanpour; Abbas Ghaderi; Mohammad Mohammadianpanah
Journal:  Oral Maxillofac Surg       Date:  2013-03-03

5.  Effects of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of ovarian carcinoma in vivo.

Authors:  Wei Li; Hong-he Zhang; Ru-jun Xu; Guang-chao Zhuo; Ye-qing Hu; Juan Li
Journal:  Med Oncol       Date:  2007-10-06       Impact factor: 3.064

6.  Potential markers for detection and monitoring of ovarian cancer.

Authors:  Brandon J D Rein; Sajal Gupta; Rima Dada; Joelle Safi; Chad Michener; Ashok Agarwal
Journal:  J Oncol       Date:  2011-04-11       Impact factor: 4.375

7.  Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts.

Authors:  Wei Li; Liang Wan; Ling-Yun Zhai; Jane Wang
Journal:  Int J Mol Sci       Date:  2014-10-23       Impact factor: 5.923

8.  Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.

Authors:  Bo Li; Shaoxi Cai; Yi Zhao; Qiyi He; Xiaodong Yu; Longcong Cheng; Yingfeng Zhang; Xiancheng Hu; Ming Ke; Sijia Chen; Misha Zou
Journal:  Oncotarget       Date:  2016-12-06

9.  Association of four genetic polymorphisms in the vascular endothelial growth factor-A gene and development of ovarian cancer: a meta-analysis.

Authors:  Chao-Huan Xu; Zhong-Hui He; Hong Xu
Journal:  Oncotarget       Date:  2017-08-21

10.  Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

Authors:  Ilary Ruscito; Dan Cacsire Castillo-Tong; Ignace Vergote; Iulia Ignat; Mandy Stanske; Adriaan Vanderstichele; Jacek Glajzer; Hagen Kulbe; Fabian Trillsch; Alexander Mustea; Caroline Kreuzinger; Pierluigi Benedetti Panici; Charlie Gourley; Hani Gabra; Marianna Nuti; Eliane T Taube; Mirjana Kessler; Jalid Sehouli; Silvia Darb-Esfahani; Elena Ioana Braicu
Journal:  Br J Cancer       Date:  2018-06-29       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.